Financings in Brief: FemRx
This article was originally published in The Gray Sheet
FemRx: Gynecological device company plans to go public with an initial offering of 2.7 mil. shares of common stock at $11 to $13 each. Proceeds would go towards sales and marketing, R&D, and "other general corporate purposes, including working capital," the firm states. Sunnyvale, California-based FemRx's initial products are the Opera Star outpatient endometrial resection/ablation specialized tissue aspirating resectoscope for use to "cut, coagulate and aspirate tissue within the uterus," and the Flo-Stat fluid management system for gynecologic procedures. Robertson, Stephens & Co. and Dillon Read & Co. are managing the offering...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.